BioVie and Mobilicom Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
BioVie and Mobilicom Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
ORLANDO, FL / ACCESSWIRE / June 21, 2024 / RedChip Companies will air interviews with BioVie, Inc. (Nasdaq:BIVI) and Mobilicom Ltd. (Nasdaq:MOB) on the RedChip Small Stocks, Big Money show, a sponsored program on Bloomberg TV, this Saturday, June 22, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.
佛罗里达州奥兰多/ACCESSWIRE/2024年6月21日/RedChip Companies将在RedChip上播出对BioVie公司（纳斯达克股票代码：BIVI）和Mobilicom Ltd.（纳斯达克股票代码：MOB）的采访 小股票，大资金 该节目是彭博电视台的赞助节目，将于美国东部时间本周六晚上7点（美国东部时间）。据估计，彭博电视在美国有7,300万个家庭可以观看。
Access the interviews in their entirety at:
访问访谈的全部内容，请访问：
BioVie:
BioVie：
Mobilicom:
Mobilicom：
In an exclusive interview, Cuong Do, President and CEO of BioVie, who will share insight into the Company's pipeline of late-stage clinical programs targeting unmet medical needs in neurodegeneration and liver disease. BioVie's lead asset, bezisterim (formerly NE3107), has demonstrated the ability to modulate TNFα production, leading to significant clinical improvements. Patients treated with bezisterim experienced reduced inflammation and insulin resistance, improved motor control and "morning on" symptoms in Parkinson's disease (PD), enhanced cognition and function, and better brain imaging scans in Alzheimer's disease (AD), as well as reduced DNA methylation levels. The Company's strategic priorities include launching a Phase 2b trial for Parkinson's in Fall 2024, initiating a Phase 3 trial for Alzheimer's in mid-2025 with a new once-daily formulation of bezisterim, continuing partnering discussions for bezisterim's geographic rights, and commencing an ascites Phase 3 trial upon identifying a suitable partner.
在一次独家采访中，BioVie总裁兼首席执行官Cuong Do将分享对该公司针对神经变性和肝病领域未得到满足的医疗需求的后期临床项目的见解。BioVie的主要资产bezisterim（前身为 NE3107）已显示出调节肿瘤坏死因子α生成的能力，从而带来了显著的临床改善。接受bezisterim治疗的患者炎症和胰岛素抵抗减轻，帕金森氏病（PD）的运动控制和 “早起” 症状得到改善，认知和功能得到增强，阿尔茨海默氏病（AD）的脑成像扫描效果更好，DNA甲基化水平降低。该公司的战略优先事项包括在2024年秋季启动帕金森氏症的2b期试验，在2025年中期启动阿尔茨海默氏症的3期试验，使用每天一次的新贝齐斯特林配方，继续就贝齐斯特林的地理权利进行合作讨论，以及在确定合适的合作伙伴后开始腹水3期试验。
Oren Elkayam, Founder and CEO of Mobilicom, appears on the RedChip Small Stocks, Big Money show on Bloomberg TV to provide a corporate update. Mobilicom presents a strong investment opportunity with its comprehensive and proprietary technology suite. The company's products, including SkyHopper Datalinks, Ground Control Systems, Mobile Mesh Networking, the ICE Cybersecurity Suite, and CONTROLiT cloud management, form the core 'brain' of drones, providing control, guidance, and cybersecurity. Mobilicom's intellectual property, comprising trade secrets and 34 patent claims across two patent families, underscores its innovation leadership. With a global footprint, the company has secured over 50 customers in 18 countries and achieved 50 "design wins," indicating significant market penetration and long-term revenue potential. Mobilicom generated 43% revenue growth with 59% gross margin in 2023, and ended the year with a strong cash balance of $8.4 million. Combined with a narrowing monthly burn rate, this affords Mobilicom a long cash runway to implement its strategic plans, capture market share, and ramp revenues.
Mobilicom 创始人兼首席执行官奥伦·埃尔卡亚姆出现在 RedChip 上 小股票，大资金 在彭博电视上播出以提供公司最新情况。Mobilicom凭借其全面的专有技术套件提供了强大的投资机会。该公司的产品，包括SkyHopper数据链接、地面控制系统、移动网状网络、ICE网络安全套件和ControLit云管理，构成了无人机的核心 “大脑”，提供控制、制导和网络安全。Mobilicom的知识产权包括商业秘密和两个专利家族的34项专利索赔，凸显了其创新领导地位。该公司业务遍及全球，已在18个国家赢得了50多名客户，并取得了50项 “设计胜利”，这表明了显著的市场渗透率和长期收入潜力。Mobilicom在2023年实现了43％的收入增长，毛利率为59％，年底现金余额强劲，为840万美元。再加上每月消耗率的缩小，这为Mobilicom提供了实施其战略计划、占领市场份额和增加收入的漫长现金流。
About BioVie Inc.
关于 BioVie Inc.
BioVie Inc. (NASDAQ: BIVI) is a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease. In neurodegenerative disease, the Company's drug candidate bezisterim inhibits inflammatory activation of ERK and NFκB (e.g., TNF signaling) that leads to neuroinflammation and insulin resistance, but not their homeostatic functions (e.g., insulin signaling and neuron growth and survival). Both are drivers of AD and PD. In liver disease, the Company's Orphan drug candidate BIV201 (continuous infusion terlipressin), with U.S. Food and Drug Administration ("FDA") Fast Track status, is being evaluated and discussed with guidance received from the FDA regarding the design of Phase 3 clinical testing of BIV201 for the treatment of ascites due to chronic liver cirrhosis. The active agent is approved in the U.S. and in about 40 countries for related complications of advanced liver cirrhosis. For more information, visit .
BioVie Inc.（纳斯达克股票代码：BIVI）是一家临床阶段的公司，开发用于治疗神经系统和神经退行性疾病以及晚期肝病的创新药物疗法。在神经退行性疾病中，该公司的候选药物bezisterim抑制ERK和NF²B（例如肿瘤坏死因子信号）的炎症激活，从而导致神经炎症和胰岛素抵抗，但不抑制其稳态功能（例如胰岛素信号传导和神经元生长和存活）。两者都是 AD 和 PD 的驱动力。在肝脏疾病方面，正在评估和讨论该公司具有美国食品药品监督管理局（“FDA”）快速通道资格的候选孤儿药 BIV201（持续输注特利加压素），并获得美国食品药品监督管理局（FDA）关于设计用于治疗慢性肝硬化引起的腹水的 BIV201 的三期临床试验的指导。该活性剂已在美国和约40个国家获准用于晚期肝硬化的相关并发症。欲了解更多信息，请访问。
About Mobilicom
关于 Mobicom
Mobilicom is a leading provider of cybersecure robust solutions for the rapidly growing defense and commercial drones and robotics market. Mobilicom's large portfolio of field-proven technologies includes cybersecurity, software, hardware, and professional services that power, connect, guide, and secure drones and robotics. Through deployments across the globe with over 50 customers, including the world's largest drone manufacturers, Mobilicom's end-to-end solutions are used in mission-critical functions.
Mobilicom 是为快速增长的国防、商用无人机和机器人市场提供网络安全可靠解决方案的领先提供商。Mobilicom 大量经过现场验证的技术产品组合包括网络安全、软件、硬件以及为无人机和机器人提供动力、连接、引导和保护的专业服务。通过在全球范围内与 50 多家客户（包括世界上最大的无人机制造商）进行部署，Mobilicom 的端到端解决方案用于关键任务功能。
For investors, please use
For company, please use
对于投资者，请使用
对于公司，请使用
About RedChip Companies
关于红筹公司
RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on microcap and small-cap companies. For 32 years, RedChip has delivered concrete, measurable results for its clients. Our newsletter, Small Stocks, Big Money, is delivered online weekly to 60,000 investors. RedChip has developed the most comprehensive service platform in the industry for microcap and small-cap companies. These services include the following: a worldwide distribution network for its stock research; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated millions of unique investor views; investor webinars and group calls; a television show, Small Stocks, Big Money, which airs weekly on Bloomberg US; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more.
RedChip Companies是一家5000公司，是一家国际投资者关系、媒体和研究公司，专注于微型股和小盘股公司。32年来，RedChip为其客户提供了具体、可衡量的业绩。我们的时事通讯， 小股票，大资金， 每周向60,000名投资者在线交付。RedChip为微型股和小盘股公司开发了业内最全面的服务平台。这些服务包括：股票研究的全球分销网络；美国主要城市的零售和机构路演；向股票经纪商、RIA、机构和家族办公室进行境外营销；产生数百万独特投资者观点的数字媒体投资者关系平台；投资者网络研讨会和群组电话；电视节目， 小股票，大资金，每周在美国彭博社播出；本地和全国市场的电视广告；企业和产品视频；网站设计；以及传统的投资者关系服务，包括新闻稿撰写、投资者演示文稿的编写、季度电话会议脚本撰写、战略咨询、筹集资金等。
To learn more about RedChip's products and services, please visit:
要了解有关RedChip产品和服务的更多信息，请访问：
"Discovering Tomorrow's Blue Chips Today"
“今天发现明天的蓝筹股”
Follow RedChip on LinkedIn:
在领英上关注 RedChip：
Follow RedChip on Facebook:
在脸书上关注 RedChip：
Follow RedChip on Instagram:
在 Instagram 上关注 RedChip
Follow RedChip on Twitter:
在推特上关注 RedChip：
Follow RedChip on YouTube:
在 YouTube 上关注 RedChip
Follow RedChip on Rumble:
在 Rumble 上关注 RedChip：
Subscribe to our Mailing List:
订阅我们的邮件列表：
Contact:
联系人：
Dave Gentry
RedChip Companies Inc.
1-407-644-4256
info@redchip.com
戴夫·金特里
RedChip Companies
1-407-644-4256
info@redchip.com
SOURCE: RedChip
来源：RedChip